Immunovia AB (publ)
IMMVF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | 0.03 | 0.00 | -0.04 |
| FCF Yield | -11.56% | -8.75% | -13.62% | -54.31% |
| EV / EBITDA | -71.75 | -9.06 | -7.85 | 6.28 |
| Quality | ||||
| ROIC | -1,953.86% | -110.12% | -64.37% | -166.98% |
| Gross Margin | 607.76% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.64 | 0.90 | 1.29 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -28.77% | -19.96% | -14.90% | -6.66% |
| Free Cash Flow Growth | -19.42% | 25.54% | 13.84% | -63.03% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 1.46 | 2.09 | -5.64 |
| Interest Coverage | -5.32 | -0.95 | -0.49 | -1,771.71 |
| Efficiency | ||||
| Inventory Turnover | 1.90 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,691.72 | 275.44 | 0.00 | 648.00 |